最聪明的狗

CME for Reviewers

The American Cancer Society with Wiley now offers continuing medical education (CME) credit for peer review of manuscripts submitted to the journal. Peer reviewers may request 3.0 AMA PRA Category 1 Credits? per original manuscript being reviewed. Reviewers may only claim CME credit once per manuscript. Credit claims for additional rounds of review will not be awarded.

To submit a request for CME credit, the manuscript reviewer must complete the required CME questions within their review submission form online. Following submission, your request for credit will then be processed. Please note that requests for CME credit are only possible during initial submission of your review.

Certificates for all approved requests will be issued out by email on a monthly basis. A copy of your certificate will be held on file by the accredited provider for later access. If you require a replacement copy of your certificates, or if you have any questions regarding the program, please contact the accredited provider at cme@wiley.com.

  • CA: A Cancer Journal for Clinicians

    Educational Objective

    Upon the completion of this activity, reviewers should be better educated in the area of oncology the article covered, prompt greater interest in the article topic, and come away with changes in practice where appropriate.

    Activity Disclosures

    No commercial support has been accepted related to the development or publication of this activity.

    Faculty and Disclosures

    Durado Brooks, Keith Delmar and Ted Gansler reported no conflicts of interest or relevant financial relationships.

    Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.

    Accreditation

    John Wiley and Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    John Wiley and Sons, Inc. designates this manuscript review activity for a maximum of 3.0 AMA PRA Category 1 Credit?. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

  • Cancer

    Educational Objective

    After reviewing an article for Cancer, reviewers should be better educated in the topic that the article covered, develop greater interest in the article topic, enhance their ability to write and review future manuscripts in the subject matter, and come away with changes in practice where appropriate.

    Activity Disclosures

    No commercial support has been accepted related to the development or publication of this activity.

    Faculty and Disclosures

    Dr. Bast receives royalties from Fujirebio Diagnostics for CA 125. He has no other financial relationships or interests to disclose.
    Dr. Batchelor serves as a consultant for Champions Biotechnology, Jiahui Health, Merck, NXDC, Amgen, Proximagen/Upsher, and GenomiCare. He also provides CME lectures/material for Up to Date. He has no other financial relationships or interests to disclose.
    Dr. Bhatia has no financial relationships or interests to disclose.
    Dr. Erasmus has no financial relationships or interests to disclose.
    Dr. Ferris serves on the advisory boards of Amgen, EMD Serono, PPD (Benetic), Lilly, and Pfizer. He receives research funding from VentiRx Pharmaceuticals. He serves on the advisory board and receives clinical trial funding from Merck. He serves on the advisory board and receives clinical trial and research funding from AstraZeneca/MedImmune and Bristol-Myers Squibb. He has no other financial relationships or interests to disclose.
    Dr. Halpern has no financial relationships or interests to disclose.
    Dr. Khuri has no financial relationships or interests to disclose.
    Dr. Kohn has no financial relationships or interests to disclose.
    Dr. Lonial serves as a consultant to Takeda, Celgene, Novartis, Bristol-Myers Squibb, Amgen, GlaxoSmithKline, Janssen, and Merck. He has no other financial relationships or interests to disclose.
    Dr. Master provided medicolegal expert testimony in 2015. He serves on the advisory boards of Janssen Oncology, Pfizer, Merck, and Agros. He has no other financial relationships or interests to disclose.
    Dr. Miller has no financial relationships or interests to disclose.最聪明的狗
    Dr. O’Brien serves as a consultant for AbbVie, Amgen, Aptose Biosciences, Alexion Pharmaceuticals, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, and Vaniam Group. She receives research support from Acerta Pharma, Kite Pharma, and Regeneron. She serves as a consultant and receives research support from Gilead Sciences, Pfizer, Pharmacyclics, Sunesis Pharmaceuticals, and TG Therapeutics. She has no other financial relationships or interests to disclose.
    Dr. O’Regan has served as an advisor for Novartis, Pfizer, Lilly, Genomic Health, Genentech, and Astellas. She received in-kind support from Lilly, Genomic Health, and Astellas. She has no other financial relationships or interests to disclose.
    Dr. Paskett is a shareholder in Seagate Technology and was previously a shareholder in Pfizer. She is the Multiple Principal Investigator of one grant funded by the Merck Foundation. She has no other financial relationships or interests to disclose.
    Dr. Posner has no financial relationships or interests to disclose.
    Dr. Ramalingam serves on scientific advisory boards for AbbVie, Amgen, AstraZeneca, Genentech, Lilly, Loxo Oncology, Merck, Nektar Therapeutics, and Roche. He has no other financial relationships or interests to disclose.
    Dr. Raut is an author on 5 sections for UpToDate (all sarcoma-related). He has no other financial relationships or interests to disclose.
    Dr. Rodriguez-Galindo has no financial relationships or interests to disclose.
    Dr. Stadler serves as a consultant to AstraZeneca, Bayer, Eisai, Sotio, Bristol-Myers Squibb, Clovis Oncology, Caremark/CVS, Genentech, and Pfizer. He is a grantee of AbbVie, AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Calithera, Exelixis, Genentech, Johnson & Johnson, Merck, Novartis, Pfizer, Seattle Genetics, Tesaro, and X4 Pharmaceuticals for clinical trials. He has no other financial relationships or interests to disclose.
    Dr. Tanabe serves as an author, editor, and consultant for UpToDate and a consultant to Best Doctors, Cancer Experts Now, and LEK Consulting. He is a board member and owns stock in Helix 12. He has a patent on EGF SNP for identification of patients at risk for hepatocellular carcinoma and a patent on the use of an EGFR inhibitor to prevent hepatocellular carcinoma but has received no license payments or royalties to date. He has no other financial relationships or interests to disclose.
    Dr. Tawbi serves as a consultant to Bristol-Myers Squibb, Novartis, Merck, Genentech, and EMD Serono. He has no other financial relationships or interests to disclose.
    Dr. Wagner is a member of Celgene’s Connect Multiple Myeloma Scientific Steering Committee. This constitutes a significant relationship. She has no other financial relationships or interests to disclose.
    Dr. Willett has no financial relationships or interests to disclose.最聪明的狗

    Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.

    Accreditation

    John Wiley and Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    John Wiley and Sons, Inc. designates this manuscript review activity for a maximum of 3.0 AMA PRA Category 1 Credit?. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

  • Cancer Cytopathology

    Educational Objective

    After reviewing an article for Cancer Cytopathology, reviewers should be better educated in the cytopathological issue that the article covered, develop greater interest in the article topic, and come away with changes in practice where appropriate.

    Activity Disclosures

    No commercial support has been accepted related to the development or publication of this activity.

    Faculty and Disclosures

    Gilda da Cunha Santos discloses the following relevant financial relationship: consultant for training in the assessment of PDL1 immunohistochemistry for Merck.
    Martha B. Pitman discloses the following relevant financial relationship: consultant on needle design and research for Boston Scientific and Medtronic, Inc.

    William Clay Faquin, Celeste N. Powers and Esther Diana Rossi reported no conflicts of interest or relevant financial relationships.

    Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.

    最聪明的狗 Accreditation

    John Wiley and Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    John Wiley and Sons, Inc. designates this manuscript review activity for a maximum of 3.0 AMA PRA Category 1 Credit?. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

网站地图